PDT COMBINED WITH IMMUNOTHERAPY
THE SCIENCE AND CHINA'S CLINICAL TRIAL PROGRAMME

Understanding why PDT and immunotherapy are compelling combination partners requires understanding how PDT kills tumour cells — and what happens to the immune system in the process.

“PDT doesn't just kill tumour cells — it kills them in a way that the immune system notices, responds to, and potentially acts on elsewhere in the body. Checkpoint inhibitors amplify that response from local to systemic.”

• Immunogenic Cell Death (ICD) — PDT's Immune Mechanism

  PDT-induced reactive oxygen species cause a specific pattern of cell death known as immunogenic cell death (ICD) — characterised by the release of damage-associated molecular patterns (DAMPs): calreticulin exposure on the cell surface, HMGB1 release, and ATP secretion. These molecular signals act as "eat me" and "danger" signals that activate dendritic cells and initiate an adaptive anti-tumour immune response.

• Dendritic Cell Activation and T-Cell Priming

  DAMPs released by PDT-treated tumour cells activate dendritic cells — the professional antigen-presenting cells of the immune system. Activated dendritic cells take up tumour antigens, travel to lymph nodes, and prime cytotoxic T cells (CD8+ T cells) to recognise and attack tumour cells bearing the same antigens. This creates tumour-specific immune memory.

• PD-L1 Upregulation After PDT — The Checkpoint Inhibitor Bridge

  PDT treatment upregulates PD-L1 expression on surviving tumour cells and in the tumour microenvironment — a compensatory immune suppression mechanism triggered by inflammation. This upregulation creates a "target" for anti-PD-1/PD-L1 checkpoint inhibitors: by blocking this post-PDT PD-L1 upregulation, checkpoint inhibitors allow the PDT-activated immune response to proceed without being switched off.

• Potential Abscopal Effect

  In some patients, the immune response activated by local PDT treatment appears to affect tumour deposits at distant sites — an abscopal-like effect. This systemic immune activation is precisely what makes the PDT + checkpoint inhibitor combination so scientifically compelling. Clinical evidence for the abscopal effect with PDT is still accumulating, but preclinical data is strong.

China is leading global clinical investigation of PDT + immunotherapy combinations. The driving factors: China's large cancer burden providing patient populations for trials, the availability of China's domestically developed photosensitisers (particularly DVDMS/sinoporphyrin sodium), and the rapid Chinese regulatory pathway for novel combination trials.

• DVDMS (Sinoporphyrin Sodium) + PD-1 Inhibitors

  DVDMS, a China-developed second-generation photosensitiser, is the primary agent in China's PDT+immunotherapy trials. Its advantageous photophysical properties (stronger singlet oxygen generation, activatable at 630 nm) make it particularly suited to generating immunogenic cell death. Multiple Chinese centres are investigating DVDMS + anti-PD-1 (sintilimab, camrelizumab, tislelizumab, nivolumab) combinations in solid tumour indications.

• Head and Neck Cancer: The Lead Indication

  Head and neck squamous cell carcinomas (HNSCC) — including oropharyngeal, hypopharyngeal, and laryngeal cancers — are the primary indication in Chinese PDT+immunotherapy trials. The mucosal accessibility for PDT delivery combined with PD-L1 expression patterns in HNSCC makes this an ideal test case. Sun Yat-sen University, Fudan University, and CAMS host active trials.

• Oesophageal SCC: High-Priority Chinese Indication

  Oesophageal squamous cell carcinoma has very high incidence in China. Phase I/II trials combining endoscopic Photofrin or DVDMS PDT with anti-PD-1 immunotherapy for unresectable or recurrent oesophageal SCC are ongoing. The strong PD-L1 expression in Chinese oesophageal SCC and PDT's established delivery route make this an important combination indication.

• Nasopharyngeal Carcinoma: The China-Specific Trial

  Given China's unique NPC burden and PDT expertise for NPC recurrence, several Chinese trials are investigating endoscopic PDT + PD-1 inhibitors for locally recurrent NPC after radiotherapy. EBV-associated NPC has distinct immunogenic features that may enhance the PDT+immunotherapy synergy.

Active and recently completed Chinese trials investigating PDT combined with checkpoint inhibitors. Trial details change frequently; CancerFax verifies current enrolment status.

The science is compelling. The clinical evidence, for now, is early. Patients considering PDT + immunotherapy combination trials deserve honest assessment of what is known and what is not.

• Strong Preclinical Evidence

  Animal model data consistently shows synergy between PDT and checkpoint inhibitors — including abscopal effects and enhanced survival compared to either treatment alone. The mechanistic rationale is well-established. This preclinical consistency makes the combination scientifically credible.

• Early-Stage Clinical Evidence

  Most Chinese PDT + immunotherapy trials are phase I/II — focused on safety, dosing, and preliminary efficacy signals. Phase III randomised trial evidence does not yet exist. The response rates reported in early trials (typically 30–60% in heavily pre-treated patients) are promising but must be interpreted cautiously without randomised comparison arms.

• Reasonable Conclusion for Patients

  For patients with appropriate tumour types who have exhausted standard options and want access to a scientifically rational combination, enrolling in a Chinese PDT + immunotherapy trial is reasonable. The underlying science is sound; safety signals from phase I are generally acceptable; and these trials represent the global frontier of this approach.

Related PDT topics and resources.

Frequently Asked Questions

Common questions about PDT + immunotherapy combinations.